Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Head & Neck 1Genitourinary 1Breast 1

Conditions

Prostatic Neoplasms 1Hypocalcemia 1Hyperparathyroidism, Secondary 1Breast Neoplasms 1Bone Neoplasms 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Calcifediol × Clear all
NCT02274623 2019-09-27

Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic Acid

OPKO Health, Inc.

Phase 1 Completed
33 enrolled
BreastGenitourinaryHead & NeckSarcoma

Bone Neoplasms, Breast Neoplasms, Hyperparathyroidism, Secondary, Hypocalcemia, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡